Education
About Us
Working with TipRanks
Follow Us
Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
CONCORDBIO Stock Chart & Stats
₹1338.60
₹62.10(2.74%)
At close: 4:00 PM EST
₹1338.60
₹62.10(2.74%)
Day’s Range― - ―
52-Week Range₹1,056.75 - ₹2,149.90
Previous CloseN/A
Volume295.44K
Average Volume (3M)12.81K
Market Cap
₹112.79B
Enterprise Value₹128.62B
Total Cash (Recent Filing)₹3.18B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)36.8
Beta1.20
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)6.30
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio2.27
Price to Book (P/B)9.60
Price to Sales (P/S)14.50
P/FCF Ratio127.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low-leverage Balance SheetA low debt-to-equity profile and high equity ratio underpin financial resilience and flexibility. This durable strength reduces refinancing risk, preserves capacity to fund capex or regulatory compliance, and supports long-term investment in fermentation capacity without stressing cash flows.
Consistent Operating Cash GenerationReliable and growing operating cash flow indicates strong cash conversion from operations, enabling self-funded reinvestment in manufacturing, process development and working capital. Over months, this supports capacity utilization improvements and reduces dependence on external financing for growth.
Specialized Fermentation API CapabilitiesExpertise in complex, fermentation-based APIs creates high technical barriers to entry and durable customer relationships. This specialization supports pricing power, long-term supply contracts in immunosuppressants and oncology, and resilience versus generic commoditized API competitors.
Bears Say
Inconsistent Free Cash Flow GrowthFluctuating free cash flow growth complicates multi-year planning for capacity expansion and R&D. Even with positive operating cash flow, variability may force timing shifts of investments or occasional external financing to fund larger projects, limiting steady capital allocation.
Slight Gross Margin PressureA decline in gross margin suggests emerging cost or yield pressures in fermentation or downstream processing. If persistent, margin erosion can reduce operating leverage benefits and compress long-term profitability unless offset by process improvements or price adjustments.
Customer/product Concentration RiskMaterial reliance on a limited set of products or customers raises structural revenue volatility and bargaining risk. Loss of a major contract or regulatory/quality disruption for a key API could meaningfully reduce revenue and underutilize specialized capacity over months.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹1056.75 and its highest was ₹2149.90 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹112.79B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is May 21, 2026 which is in 84 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Feb 11, 2026. The company reported ₹6.3 earnings per share for the quarter, missing the consensus estimate of ₹7.2 by -₹0.9.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Notavailable dividend of ₹10.7 which represents an annual dividend yield of 0.8%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹6.3 in its last earnings report, missing expectations of ₹7.2. Following the earnings report the stock price went down -3.042%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―